Patents Examined by Kara R McMillian
  • Morphinan derivatives for the treatment of drug overdose
    Patent number: 9119848
    Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: September 1, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Bernard Silverman, Fen-Ni Fu, Chengyun Guo
  • Stable bortezomib formulations
    Patent number: 9107821
    Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: August 18, 2015
    Assignee: Innopharma, Inc.
    Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
  • Systems and methods for balancing and maintaining the health of the human autonomic nervous system
    Patent number: 9079030
    Abstract: A protocol or procedure is provided for lowering sympathetic nervous system arousal in a person in order to prepare that person for a medical or dental procedure. First, a therapeutic dosage of one or more neurotransmitter supplements, such as a gamma aminobutyric acid formulation, a tryptophan-derived neurotransmitter precursor, and dehydroepiandrosterone are administered to the patient. Concomitantly, gelled electrodes are placed adjacent or below the mastoid. The gelled electrodes are connected to a cranial electrotherapy stimulation device that administers a sub-sensation level current to the patient. Also, a noise dampening headset is placed on the patient and a neuroacoustic entrainment recording or program is played. Next, light is blocked with black out glasses. Then, the medical or dental procedure is performed.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: July 14, 2015
    Inventor: G. Blake Holloway
  • Na/K-ATPase ligand
    Patent number: 9072751
    Abstract: Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: July 7, 2015
    Assignee: The University of Toledo
    Inventors: Zi-Jian Xie, Joseph I. Shapiro
  • Injectable ibuprofen formulation
    Patent number: 9072661
    Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 7, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Andrew Vila
  • Injectable ibuprofen formulation
    Patent number: 9072710
    Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 7, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Andrew Vila
  • Stable bortezomib formulations
    Patent number: 9061037
    Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 23, 2015
    Assignee: Innopharma, Inc.
    Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
  • Compounds and assays for controlling Wnt activity
    Patent number: 9052324
    Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: June 9, 2015
    Assignee: Enzo Biochem, Inc.
    Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
  • Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
    Patent number: 9040557
    Abstract: The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 26, 2015
    Assignee: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC.
    Inventor: Tae Sun Park
  • Levothyroxine formulations
    Patent number: 9006289
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: April 14, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Zhi-Qiang Jiang, Arunya Usayapant, George Monen
  • 8-hydroxy quinoline derivatives
    Patent number: 8975278
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: March 10, 2015
    Assignee: Prana Biotechnology Limited
    Inventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
  • Compositions and methods for bone formation and modeling
    Patent number: 8969339
    Abstract: The present disclosure is directed to methods of identifying a compound that binds to or interacts with a protein receptor involved in bone formation. Specifically, the disclosure is directed to methods of identifying a compound that regulates a Wnt pathway in a cell by binding to or interacting with cavities in proteins such as LRP5, LRP 6 and/or frizzled receptor and interfering with receptor binding to other proteins in a Wnt pathway. The present disclosure is further directed to methods and compositions that comprise an identified compound for treating or preventing a disease in a mammal in which Wnt pathway suppression plays a role.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: March 3, 2015
    Assignee: Enzo Biochem, Inc.
    Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
  • Treatment of length dependent neuropathy
    Patent number: 8962668
    Abstract: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with ?-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds are delivered to or adjacent to painful areas in patients with painful length dependent neuropathy, and other neuropathies that affect the pain signaling fibers in the skin. A preferred compound for the treatment of patients with length dependent neuropathy is clonidine applied in a transdermal patch, gel, ointment, lotion, liposomal formulation, cream, or emulsion, wherein the concentration is sufficient to provide an effective dose in the painful area or immediately adjacent areas.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Arcion Therapeutics, Inc.
    Inventor: James N. Campbell
  • Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids
    Patent number: 8957110
    Abstract: The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (?-linolenic acid), mixed with vitamin E acetate and formulated in a stable composition in hydrogel, i.e. in dispersed form in an aqueous vehicle containing one or more gelling polymers. The proposed compositions are particularly indicated for use as artificial tears.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: February 17, 2015
    Assignee: TRB Chemedica International S.A.
    Inventors: Danilo Aleo, Stefano Barabino, Sergio Mangiafico, Maurizio Rolando, Maria Grazia Antonietta Saita
  • Methods for improving cognitive function
    Patent number: 8946206
    Abstract: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Craig C. Garner, H. Craig Heller, Damien Colas, Daniel Z. Wetmore
  • Non-aqueous pharmaceutical composition
    Patent number: 8946208
    Abstract: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100% by volume of N-methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: February 3, 2015
    Assignee: Archimedes Development Limited
    Inventors: Jonathan Castile, Alan Smith, Yu-Hui Cheng, Peter James Watts
  • Na/K-ATPase ligand
    Patent number: 8906891
    Abstract: This process relates to a pharmaceutical composition of an Na—K-ATPase ligand which will stimulate Na/K-ATPase signaling in a pharmaceutically acceptable vehicle. In one embodiment, the composition may be used to treat a skin disorder. In another embodiment, the composition may be used to inhibit cardiac fibrosis.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: December 9, 2014
    Assignee: The University of Toledo
    Inventors: Zijian Xie, Joseph I. Shapiro
  • Topical therapy for the treatment of migraines, muscle sprains, muscle spasms, spasticity and related conditions
    Patent number: 8883830
    Abstract: The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Afgin Pharma LLC.
    Inventor: Ronald Aung-Din
  • Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
    Patent number: 8841300
    Abstract: A new treatment methodology and pharmacological composition for the treatment and remission of Parkinson's Disease and other neurological diseases are provided. The medication and treatment are based on the use of a combination of a phosphodiesterase inhibitor medication, commonly used to treat male erectile dysfunction, and a high-dose of serotonergic synaptic reuptake inhibitor medication, commonly used to treat depression, anxiety disorders, obsessive compulsive disorder and various panic phobias. The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: September 23, 2014
    Inventor: Jerry M. Held
  • Synthesis of novel antimicrobials
    Patent number: 8835476
    Abstract: The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: September 16, 2014
    Inventors: Fan Wu, Donald Weaver, Chris Barden, Christopher McMaster, David Byers, Annette Henneberry, Fuqiang Ban